ITI Life Sciences Launches New R&D Program: £5.5 Million To Develop New Predictive Safety Models For Early Drug Development

Published: Feb 24, 2005

ITI Life Sciences (Dundee, Scotland), together with CXR Biosciences (Dundee) and Artemis Pharmaceuticals (Cologne, Germany), today announces the launch of a new £5.5 million R&D programme to develop new screening and safety models to more accurately predict the effects of drug compounds and their breakdown products in the human body.

Back to news